0
BioNTech SE Banner Image

BioNTech SE

  • Ticker BNTX
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
BioNTech SE Logo Image
  • 1001-5000 Employees
  • Based in Mainz, Germany
Biopharmaceutical New Technologies is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. The Company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-basedMore therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules. Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, including Genmab, Sanofi, Bayer Animal Health, Genentech, a member of the Roche Group, Regeneron, Genevant, Fosun Pharma, and Pfizer.
BioNTech SE

Most Recent Responsibility Report

BioNTech SE
MOST RECENT 2022 Sustainability Report

BioNTech SE does not currently have any hardcopy reports on ResponsibilityReports.com. Click the button below to request a report when hardcopies become available.

Request Information

Archived Responsibility Reports

Our service enables potential investors to review the most recent and archived BioNTech SE Sustainability Report, BioNTech SE Corporate Social Responsibility Report, BioNTech SE CSR Report, BioNTech SE Corporate Responsibility, BioNTech SE CR Report, BioNTech SE Citizenship Report, BioNTech SE ESG Report, and BioNTech SE Environmental Report online.
BioNTech SE Logo Image

Rate This Report

Your vote helps our reports be more useful
Rating Saved!

Thank you for your feedback!